Scaling Up Novel Therapies: Platform processes have improved monoclonal antibody scale-up Can they do the same for personalized therapies?
| Publicado en: | BioPharm International Vol. 31; no. 11; pp. 14 - 17 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
MJH Life Sciences
Nov2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132933008&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 132933008 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1542166X 5NE jtl: BioPharm International issn: 1542166X maglogo: N pubinfo: dt: Nov2018 vid: 31 iid: 11 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 132933008 132933008 ppf: 14 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Scaling Up Novel Therapies: Platform processes have improved monoclonal antibody scale-up Can they do the same for personalized therapies? aug: au: SHANLEY, AGNES sug: pubtype: Trade Publication doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|